Virginia Kaklamani

Professor

University of Texas Health Science Center at San Antonio
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (11)

mTTNT benefit in clinical subgroups: ( A ) 1–2 prior lines of ET ± CDK4/6i, ( B ) 1–2 prior lines of ET ± CDK4/6i ≥ 12 months, ( C ) 1 prior line of ET ± CDK4/6i, ( D ) 2 prior lines of ET ± CDK4/6i, ( E ) ≥3 prior lines of ET ± CDK4/6i, ( F ) visceral metastasis, ( G ) coexisting ESR1 and PI3K pathway mutations, ( H ) no prior fulvestrant, and ( I ) no prior chemotherapy.

Year:

2026

Purpose: The EMERALD trial led to the approval of elacestrant for estrogen receptor (ER)–positive, HER2-negative, estrogen receptor 1 ( ESR1 )–mutated advanced or metastatic breast cancer (mBC) with disease progression following at least one line of endocrine therapy (ET). Subgroup analyses provided evidence suggesting that elacestrant enables ET sequencing in the second line before other targeted combinations, which could delay chemotherapy-based regimens. Experimental Design: This study used claims data from the Komodo Research Dataset linked with Foundation Medicine Inc. clinical genomic data from patients with estrogen receptor+/HER2− mBC harboring an ESR1 mutation treated with elacestrant. The primary outcome measure was time to next treatment (TTNT). Results: Among 306 patients, 93.8% had prior ET ± cyclin-dependent kinase 4/6 inhibitor for ≥12 months, 50.0% had prior chemotherapy, and 72.2% had prior fulvestrant. Median TTNT (mTTNT) was 8.2 months [95% confidence interval (CI), 6.3–13.0] in patients with 1 to 2 prior lines and 7.5 months (95% CI, 7.1–9.9) in those with ≥3 prior lines of ET. In patients with coexisting ESR1 - and PI3K-pathway–mutated tumors, mTTNT was 6.3 months (95% CI, 4.8–7.9). mTTNT was 7.9 months (95% CI, 7.1–9.8) in all patients and was also sustained in patients with no prior fulvestrant [12.9 months (95% CI, 7.2–not reached)], no prior chemotherapy [8.4 months (95% CI, 7.1–13.3)], visceral metastasis [7.9 months (95% CI, 7.0–9.9)], and liver metastases [7.2 months (95% CI, 6.3–9.0)]. Conclusions: Elacestrant demonstrated a durable benefit in real-world clinical practice, particularly in earlier lines and in patients with prolonged prior ET exposure. Despite coexisting ESR1 and PI3K pathway mutations, TTNT remained clinically meaningful, reinforcing the role of elacestrant in personalized ET sequencing strategies prior to chemotherapy, antibody–drug conjugates, or targeted combinations. See related article by Lloyd et al., p. 169

Year:

2026

PURPOSE Goserelin is a gonadotropin-releasing hormone agonist for ovarian function suppression in the treatment of pre- and perimenopausal patients with breast cancer and for the preservation of ovarian function during chemotherapy. Goserelin is available in doses of 3.6 mg once every 4 weeks or 10.8 mg once every 12 weeks. This study used US real-world evidence to characterize goserelin treatment patterns. METHODS Electronic health record data of adults with a history of breast cancer and ≥2 goserelin prescriptions between January 1, 2017, and December 31, 2022, were identified through TriNetX. Patient demographics and treatment patterns were examined. RESULTS Overall, 3,620 US patients were identified: 2,870 treated with goserelin 3.6 mg once every 4 weeks, 410 treated with 10.8 mg once every 12 weeks, and 340 switched from 3.6 mg once every 4 weeks to 10.8 mg once every 12 weeks. Peak utilization of 10.8 mg once every 12 weeks (36.6%) and dose switching to 10.8 mg once every 12 weeks (26.5%) occurred in 2020. Patients who switched to 10.8 mg once every 12 weeks had the longest median treatment duration (776 days), compared with the 3.6 mg once every 4 weeks and 10.8 mg once every 12 weeks cohorts (264 and 429 days, respectively). Of patients who switched, 65% were still being treated after 2 years, compared with 30% and 40% treated with 3.6 mg once every 4 weeks only or 10.8 mg once every 12 weeks only, respectively. Patients initially treated with or who switched to 10.8 mg once every 12 weeks were more adherent (64.4%-75.0%), compared with patients treated with 3.6 mg once every 4 weeks (45.4%). CONCLUSION Treatment with goserelin 10.8 mg once every 12 weeks is associated with greater adherence and longer treatment duration, compared with 3.6 mg once every 4 weeks in patients with breast cancer in the United States.

Year:

2026

This pilot phase II study evaluated the combination of lenvatinib, a multi‐kinase inhibitor, and eribulin, a microtubule inhibitor, in patients with advanced solid tumors, including breast carcinoma, lung carcinoma, and sarcoma. Tumor angiogenesis and resistance mechanisms to anti‐angiogenic therapies were primary motivations for combining these agents. The trial enrolled 29 patients, heavily pretreated with at least three prior lines of chemotherapy, and aimed to assess the efficacy and safety of the combination therapy. Overall response rate (ORR) was 24% with the highest responses observed in breast cancer (29%) and lung cancer (33%) patients. Median progression‐free survival (PFS) was 7.4 months (95% CI 4.5, NA), and overall survival (OS) was 8.2 months (95% CI 6.4 to 14.9). A significant improvement in both OS and PFS was found in vimentin‐negative patients, suggesting that vimentin expression may be a predictor of treatment response. The most common treatment‐related adverse events (TRAEs) were oral mucositis, fatigue, neutropenia, and nausea. Grade ≥3 TRAEs included neutropenia (34.5%), febrile neutropenia (17.2%), and hypertension (13.8%), with one fatal case of sepsis reported. While the study demonstrated the potential of lenvatinib and eribulin in advanced solid tumors, particularly breast and lung cancers, it also highlighted the need for further investigation into biomarkers like vimentin to predict therapeutic outcomes. The combination therapy was manageable in terms of safety and toxicity, with a predictable safety profile. These findings suggest that lenvatinib and eribulin represent a promising treatment strategy for advanced, heavily pretreated solid tumors, warranting further exploration in larger clinical studies.

Year:

2025

Purpose Clinical trials demonstrated every 3-month goserelin 10.8 mg to be non-inferior to monthly goserelin 3.6 mg in premenopausal patients with ER-positive breast cancer. However, real-world studies comparing 3-month goserelin 10.8 mg with monthly goserelin 3.6 mg are scarce. Methods Electronic medical records from the ConcertAI Patient360™ database were analyzed in U.S. patients exposed to goserelin 3.6 mg or 10.8 mg post-breast cancer diagnosis. Inverse probability of treatment weighting (IPTW) was used to ensure the comparability between the two cohorts (goserelin 3.6 mg and goserelin 10.8 mg). The non-inferiority of goserelin 10.8 mg compared with goserelin 3.6 mg was assessed by 12-month real-world event-free survival (rwEFS) rates (− 15% margin) for the overall group of patients and separately for patients with early-stage/locally advanced and metastatic breast cancer. Results A total of 575 patients received goserelin 3.6 mg and 123 received goserelin 10.8 mg. Goserelin 10.8 mg was non-inferior to goserelin 3.6 mg based on observed 12-month rwEFS rates (79.2% versus 76.6%, respectively; treatment difference 2.7%). Goserelin 10.8 mg was observed to be non-inferior in patients who initiated goserelin in early-stage/locally advanced (treatment difference − 2.3%) and metastatic (treatment difference 10.4%) breast cancer. Conclusion This real-world analysis indicates that 3-month goserelin 10.8 mg is non-inferior to monthly 3.6 mg among premenopausal women with breast cancer in terms of 12-month rwEFS rate. These findings may support the use of the 3-month goserelin 10.8 mg as an alternative treatment option to monthly goserelin 3.6 mg for this patient population.

Year:

2025

Purpose: Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER + ), HER2 − metastatic breast cancer and tumors harboring estrogen receptor 1 ( ESR1 ) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i). In patients with ESR1 -mutated tumors, we evaluated the efficacy and safety of elacestrant versus SOC based on prior ET+CDK4/6i duration and in clinical subgroups with prior ET+CDK4/6i ≥12 months. Patients and Methods: EMERALD, an open-label phase III trial, randomly assigned patients with ER + , HER2 − metastatic breast cancer who had received 1–2 prior lines of ET, mandatory CDK4/6i, and ≤1 chemotherapy to elacestrant (345 mg daily) or SOC (aromatase inhibitor or fulvestrant). PFS was assessed across subgroups in post hoc exploratory analyses without adjustment for multiple testing. Results: In patients with ESR1 -mutated tumors and prior ET+CDK4/6i ≥12 months, the median PFS for elacestrant versus SOC was 8.6 versus 1.9 months (HR, 0.41; 95% confidence interval, 0.26–0.63). In this population, the median PFS (in months) for elacestrant versus SOC was 9.1 versus 1.9 (bone metastases), 7.3 versus 1.9 (liver and/or lung metastases), 9.0 versus 1.9 ( PIK3 catalytic subunit α mutation), 8.6 versus 1.9 (tumor protein p53 gene mutation), 9.0 versus 1.9 (HER2-low), 9.0 versus 1.9 ( ESR1 D538G -mutated tumors), and 9.0 versus 1.9 ( ESR1 Y537S/N -mutated tumors). Subgroup safety was consistent with the overall population. Conclusions: The duration of prior ET+CDK4/6i ≥12 months in metastatic breast cancer was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC and was consistent across all subgroups evaluated in patients with ER + , HER2 − , ESR1 -mutated tumors.

Year:

2024

PFS according to mutation and molecular expression subgroups. Kaplan–Meier estimates of PFS in patients with ESR1 -mutated tumors and prior ET+CDK4/6i ≥12 months who, at screening, had the presence of ( A ) PIK3CA -mut ( n = 62; 39%); ( B ) PIK3CA wild-type ( n = 97; 61%); ( C ) TP53 -mut ( n = 61; 38%); ( D ) TP53 wild-type ( n = 97; 61%); ( E ) HER2-low expression ( n = 77; 48%); ( F ) HER2-zero expression ( n = 69; 43%); ( G ) ESR1 D538G -mutated tumors ( n = 97; 61%); or ( H ) ESR1 Y537S/N -mutated tumors ( n = 92; 58%). a Includes the following PIK3CA -mut: E545K, H1047R, and E542K among others. b Data not available for all patients. c HER2-low expression defined as IHC score of 1+ or 2+ with no amplification by ISH.

Year:

2024

PFS in patients who received prior ET+CDK4/6i ≥12 months in the metastatic setting. Kaplan–Meier estimates of PFS in patients with ESR1 -mutated tumors and prior ET+CDK4/6i ≥12 months in the metastatic setting ( n = 159).

Year:

2024

PFS according to clinical subgroups. Kaplan–Meier estimates of PFS in patients with ESR1 -mutated tumors and prior ET+CDK4/6i ≥12 months who, at screening, had the presence of ( A ) bone metastases ( n = 136; 86%); ( B ) liver and/or lung metastases ( n = 113; 71%); ( C ) n = 82; 52%); or ( D ) ≥3 metastatic sites ( n = 53; 33%). a Eighty-five percent of patients had bone and other sites of metastases (30% of these patients had no liver or lung involvement). b Fifty-five percent of patients had liver and other sites of metastases (10% of these patients had no lung or bone involvement); 25% of patients had lung and other sites of metastases (2% of these patients had no liver or bone involvement). c The number of metastatic sites was available for 135 of 159 patients with ESR1 -mutated tumors and prior ET+CDK4/6i ≥12 months.

Year:

2024

Purpose: Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER+), HER2− metastatic breast cancer and tumors harboring estrogen receptor 1 (ESR1) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i). In patients with ESR1-mutated tumors, we evaluated the efficacy and safety of elacestrant versus SOC based on prior ET+CDK4/6i duration and in clinical subgroups with prior ET+CDK4/6i ≥12 months. Patients and Methods: EMERALD, an open-label phase III trial, randomly assigned patients with ER+, HER2− metastatic breast cancer who had received 1–2 prior lines of ET, mandatory CDK4/6i, and ≤1 chemotherapy to elacestrant (345 mg daily) or SOC (aromatase inhibitor or fulvestrant). PFS was assessed across subgroups in post hoc exploratory analyses without adjustment for multiple testing. Results: In patients with ESR1-mutated tumors and prior ET+CDK4/6i ≥12 months, the median PFS for elacestrant versus SOC was 8.6 versus 1.9 months (HR, 0.41; 95% confidence interval, 0.26–0.63). In this population, the median PFS (in months) for elacestrant versus SOC was 9.1 versus 1.9 (bone metastases), 7.3 versus 1.9 (liver and/or lung metastases), 9.0 versus 1.9 (<3 metastatic sites), 10.8 versus 1.8 (≥3 metastatic sites), 5.5 versus 1.9 (PIK3 catalytic subunit α mutation), 8.6 versus 1.9 (tumor protein p53 gene mutation), 9.0 versus 1.9 (HER2-low), 9.0 versus 1.9 (ESR1D538G-mutated tumors), and 9.0 versus 1.9 (ESR1Y537S/N-mutated tumors). Subgroup safety was consistent with the overall population. Conclusions: The duration of prior ET+CDK4/6i ≥12 months in metastatic breast cancer was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC and was consistent across all subgroups evaluated in patients with ER+, HER2−, ESR1-mutated tumors.

Year:

2024

Year:

2024

Collaborators (7)

Joyce O'Shaughnessy

Baylor University Medical Center

UNITED STATES
View details

Patrick Neven

University Hospitals Leuven

BELGIUM
View details

Maryam Lustberg

Yale University

UNITED STATES
View details

Francois-Clement Bidard

Professor of Medical Oncology

Institut Curie

FRANCE
View details

Hope Rugo

Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology

City Of Hope National Medical Center

UNITED STATES
View details

Aditya Bardia

UCLA Health

UNITED STATES
View details

Reshma Mahtani

Chief of Breast Medical Oncology

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES
View details